238811
Cdk9 Inhibitor II
The Cdk9 Inhibitor II, also referenced under CAS 140651-18-9, controls the biological activity of Cdk9. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
别名:
Cdk9 Inhibitor II, 4-(3,5-Diamino-1H-pyrazol-4-ylazo)-phenol
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H10N6O
化学文摘社编号:
分子量:
218.22
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
产品名称
Cdk9 Inhibitor II, The Cdk9 Inhibitor II, also referenced under CAS 140651-18-9, controls the biological activity of Cdk9. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
SMILES string
[nH]1nc(c(c1N)N=Nc2ccc(cc2)O)N
InChI
1S/C9H10N6O/c10-8-7(9(11)15-14-8)13-12-5-1-3-6(16)4-2-5/h1-4,16H,(H5,10,11,14,15)
InChI key
AYZRKFOEZQBUEA-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
orange
solubility
DMSO: 10 mg/mL
ethanol: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Cdk9
Cdk9
Product competes with ATP.
Reversible: no
Target IC50: 350 nM, using Cdk9/T1
Disclaimer
Toxicity: Irritant (B)
General description
A cell-permeable azo-pyrazole compound that acts as a potent, ATP-competitive, and Cdk9-selective inhibitor (IC50 = 350 nM, using Cdk9/T1). It inhibits Cdk1/B, Cdk2/E, Cdk2/A, Cdk4/D1, Cdk7/H, and p70S6K only at much higher concentrations (IC50 = 44, 20, 69, 13.5, 26, and 10 µM, respectively) and shows little or no activity against eight other commonly studied kinases even at concentrations as high as 10 µM. Shown to exhibit antiproliferative activity in human tumor cell lines.
Other Notes
Krystof, V., et al. 2006. J. Med. Chem.49, 6500.
Packaging
Packaged under inert gas
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
XinTao Gao et al.
Molecular oncology, 15(7), 1901-1920 (2021-05-02)
Androgen receptor (AR) is the principal molecule in prostate cancer (PCa) etiology and therapy. AR re-activation still remains a major challenge during treatment of castration-resistant prostate cancer (CRPC) tumors that relapse after castration therapies. Recent reports have indicated the enrichment
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持